Acute Lymphoblastic Leukemia

Dr Cassady Reviews Phase 4 Study Results of Inotuzumab Ozagamicin in R/R ALL

12/13/2021

Ryan Cassady, MD, SCCA, discusses the safety and efficacy of low-dose inotuzumab ozagamicin in patients with relapsed or refractory ALL, presented at the 2021 ASH Annual Meeting.

Ryan Cassady, MD, SCCA,...

12/13/2021

Oncology

Conference Insider

Improved EFS With Blinatumomab vs Chemo for High-Risk First Relapse of BCP-ALL

12/03/2021

Study findings being presented at the ASH Annual Meeting suggest blinatumomab as a new standard-of-care consolidation therapy before alloHSCT in young patients with high-risk first-relapse BCP-ALL.

Study findings being presented...

12/03/2021

Oncology

Test Your Knowledge

Quiz: Enrollment Characteristics and Outcomes of US Patients With ALL

12/01/2021

A prospective Phase II clinical trial, known as ______, conducted by the U.S. Intergroup, demonstrated the feasibility of delivering a pediatric-inspired ALL regimen to newly diagnosed AYA ALL patients and found this approach to be superior...

A prospective Phase II clinical...

12/01/2021

Oncology

Conference Insider

Asciminib, DAS + Prednisone Combo Found Feasible in BCR-ABL1+ ALL

12/01/2021

Investigators sought to discover if ABL blockade with catalytic domain and allosteric inhibitors would be discovered as tolerable and effective in adult patients with BCR-ABL1+ ALL, to be presented at the 2021 Annual ASH Meeting.

Investigators sought to discover...

12/01/2021

Oncology

Test Your Knowledge

Quiz: Real-World Outcomes for R/R B-Cell ALL Treated with Tisagenlecleucel

12/01/2021

True or False: Updated registry data from ASH for pediatric and young adult patients with R/R ALL treated with tisagenlecleucel revealed that patients aged ≥18y had a greater disease burden and were more heavily pre-treated at baseline than...

True or False: Updated registry...

12/01/2021

Oncology

Videos

KTE-X19 CAR-T Therapy Demonstrates Clinical Benefit for R/R B-ALL

06/08/2021

In part 1 of this video series, Bijal Shah, MD, shares results from the phase 2 ZUMA-3 study of KTE-X19 for R/R B-ALL. These data were presented at the 2021 ASCO Annual Meeting.

In part 1 of this video series,...

06/08/2021

Oncology

Conference Insider

Induction With Inotuzumab Ozogamicin Feasible for Patients With ALL

12/16/2020

Induction therapy with inotuzumab ozogamicin followed by conventional chemotherapy has shown promise in older patients with ALL.

Induction therapy with...

12/16/2020

Oncology

Conference Insider

Inotuzumab Ozogamicin Yields Anti-Leukemia Activity in Young Patients With R/R ALL

12/11/2020

Single-agent inotuzumab ozogamicin demonstrated anti-leukemia activity in heavily pre-treated young patients with CD22+ relapsed/refractory ALL.

Single-agent inotuzumab...

12/11/2020

Oncology

Conference Insider

Venetoclax Plus Navitoclax and Chemo Effective for Lymphoblastic Lymphoma, ALL

12/03/2020

Venetoclax combined with navitoclax and chemo showed manageable safety and promising efficacy in heavily pretreated patients with ALL and lymphoblastic lymphoma.

Venetoclax combined with...

12/03/2020

Oncology

Conference Insider

Dasatinib Added to Induction Therapy Improves Outcomes in Ph+ ALL

06/19/2020

Dasatinib added to 2-step induction therapy improves pre-transplant treatment for patients with Philadelphia chromosome-positive ALL.

Dasatinib added to 2-step...

06/19/2020

Oncology